Skip to content

Clarify Pharma PLC - Result of Annual General Meeting

Announcement provided by

File Forge Technology PLC · FILE

30/05/2022 16:27

Clarify Pharma PLC - Result of Annual General Meeting
RNS Number : 2898N
Clarify Pharma PLC
30 May 2022

Press Release


30 May 2022



Clarify Pharma PLC


("Clarify Pharma" or "the Company")



Result of Annual General Meeting


Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.


For further information please contact:


Clarify Pharma

Jon Bixby

Executive Chairman

via Tancredi +44 207 887 7633




First Sentinel

Corporate Adviser

Brian Stockbridge


+44 7876 888 011

Tennyson Securities


Corporate Broker

Peter Krens

+44 207 186 9030

Tancredi Intelligent Communication

Media Relations

Catrina Daly

Emma Hodges

Salamander Davoudi


+44 7727 153 868

+44 7861 995 628

+44 7957 549 906



About Clarify Pharma PLC:


Listed on the Aquis Stock Exchange in London, Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing. The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

FILE announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal